Senior Clinical SAS Programmer & CDISC Expert

penumbrainc; United States; Sur place; USD 90 000 - 158 000; Plein temps

Résumé du poste

Penumbra is seeking a seasoned SAS statistical programmer to support analysis and regulatory submission activities for clinical trials. Under supervision, you will develop analysis programs, create datasets, listings, tables and graphs, and mentor junior staff.

You will maintain CDISC standards (SDTM/ADaM/CDASH), work with biostatisticians and data managers, ensure QMS/GCP compliance, and participate in data warehouse management. Travel about 10% is expected.

Qualifications

• Bachelor's degree in statistics/computer science or related field with 5+ years of statistical programming experience in clinical setting.
• Familiarity with CDISC guidance, regulatory submissions and data standards.
• Experience with SAS macros, SQL, and data import/export processes.

Responsabilités

• Develop algorithms and write programs to create datasets per specifications.
• Produce data listings, summary tables and graphs using SAS.
• Mentor junior programmers and ensure quality coding practices.
• Interact with project statisticians and data managers on a project team.
• Maintain CDISC standards and support regulatory submission datasets.

Connaissances

SAS programming

CDISC/CDASH/SDTM/ADaM

Clinical data standards

SAS macro programming

Data management liaison

Communication skills

Formation

Bachelor's degree in Statistics/Computer Science or related field

Outils

Base SAS

SAS/GRAPH

SAS/ODS

SAS/STAT

SAS Macro programming

Description du poste

Penumbra is seeking a seasoned SAS statistical programmer to support analysis and regulatory submission activities for clinical trials. Under supervision, you will develop analysis programs, create datasets, listings, tables and graphs, and mentor junior staff.

You will maintain CDISC standards (SDTM/ADaM/CDASH), work with biostatisticians and data managers, ensure QMS/GCP compliance, and participate in data warehouse management. Travel about 10% is expected.